JP2007523633A5 - - Google Patents

Download PDF

Info

Publication number
JP2007523633A5
JP2007523633A5 JP2006544119A JP2006544119A JP2007523633A5 JP 2007523633 A5 JP2007523633 A5 JP 2007523633A5 JP 2006544119 A JP2006544119 A JP 2006544119A JP 2006544119 A JP2006544119 A JP 2006544119A JP 2007523633 A5 JP2007523633 A5 JP 2007523633A5
Authority
JP
Japan
Prior art keywords
nucleic acid
acid molecule
immune response
pharmaceutical composition
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006544119A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007523633A (ja
JP5060134B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/041921 external-priority patent/WO2005058937A2/en
Publication of JP2007523633A publication Critical patent/JP2007523633A/ja
Publication of JP2007523633A5 publication Critical patent/JP2007523633A5/ja
Application granted granted Critical
Publication of JP5060134B2 publication Critical patent/JP5060134B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2006544119A 2003-12-12 2004-12-10 ヒト細胞傷害性Tリンパ球のエピトープ及びそのMUC−1の非VNTR(non−variablenumberoftandemrepeatsequence)由来のアゴニストエピトープ Expired - Lifetime JP5060134B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52932903P 2003-12-12 2003-12-12
US60/529,329 2003-12-12
PCT/US2004/041921 WO2005058937A2 (en) 2003-12-12 2004-12-10 A human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1

Publications (3)

Publication Number Publication Date
JP2007523633A JP2007523633A (ja) 2007-08-23
JP2007523633A5 true JP2007523633A5 (cg-RX-API-DMAC10.html) 2008-02-07
JP5060134B2 JP5060134B2 (ja) 2012-10-31

Family

ID=34699963

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006544119A Expired - Lifetime JP5060134B2 (ja) 2003-12-12 2004-12-10 ヒト細胞傷害性Tリンパ球のエピトープ及びそのMUC−1の非VNTR(non−variablenumberoftandemrepeatsequence)由来のアゴニストエピトープ

Country Status (8)

Country Link
US (3) US7999071B2 (cg-RX-API-DMAC10.html)
EP (1) EP1697399B1 (cg-RX-API-DMAC10.html)
JP (1) JP5060134B2 (cg-RX-API-DMAC10.html)
AU (1) AU2004299457B2 (cg-RX-API-DMAC10.html)
CA (1) CA2547635C (cg-RX-API-DMAC10.html)
DK (1) DK1697399T3 (cg-RX-API-DMAC10.html)
ES (1) ES2616337T3 (cg-RX-API-DMAC10.html)
WO (1) WO2005058937A2 (cg-RX-API-DMAC10.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6913697B2 (en) 2001-02-14 2005-07-05 Science & Technology Corporation @ Unm Nanostructured separation and analysis devices for biological membranes
EP1569510B1 (en) 2002-09-27 2011-11-02 The General Hospital Corporation Microfluidic device for cell separation and uses thereof
US20070196820A1 (en) 2005-04-05 2007-08-23 Ravi Kapur Devices and methods for enrichment and alteration of cells and other particles
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
EP2029779A4 (en) 2006-06-14 2010-01-20 Living Microsystems Inc HIGHLY PARALLEL SNP GENOTYPING UTILIZATION FOR FETAL DIAGNOSIS
US8372584B2 (en) 2006-06-14 2013-02-12 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
WO2008011672A1 (en) * 2006-07-25 2008-01-31 4G Vaccines Pty Ltd A cancer vaccine comprising a mucin 1 (muc1) t cell epitope-derived peptide
CA2665816C (en) * 2006-09-21 2016-07-12 Vaxil Biotherapeutics Ltd. Antigen specific multi epitope vaccines
ES2725450T3 (es) 2007-07-02 2019-09-24 Etubics Corp Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples
KR101543624B1 (ko) 2007-08-20 2015-08-11 온코세라피 사이언스 가부시키가이샤 Foxm1 펩티드 및 이를 포함하는 약학적 조성물
WO2010033578A2 (en) 2008-09-20 2010-03-25 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
TWI469791B (zh) 2009-02-18 2015-01-21 Oncotherapy Science Inc Foxm1胜肽以及含此胜肽之疫苗
US9346998B2 (en) 2009-04-23 2016-05-24 The University Of Chicago Materials and methods for the preparation of nanocomposites
CN109010809A (zh) 2011-08-17 2018-12-18 全球免疫股份有限公司 酵母-muc1免疫治疗组合物及其用途
WO2013103658A1 (en) * 2012-01-03 2013-07-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Native and agonist ctl epitopes of the muc1 tumor antigen
CN103570821A (zh) * 2012-07-27 2014-02-12 北京智飞绿竹生物制药有限公司 粘蛋白-1抗原性多肽及其作为肿瘤疫苗的用途
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
AU2014340201B2 (en) 2013-10-23 2019-02-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
AU2016205215B2 (en) 2015-01-09 2021-03-11 Etubics Corporation Methods and compositions for combination immunotherapy
US10695417B2 (en) 2015-01-09 2020-06-30 Etubics Corporation Human adenovirus serotype 5 vectors containing E1 and E2B deletions encoding the ebola virus glycoprotein
US11149087B2 (en) 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy
WO2017070632A2 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
US20190183870A1 (en) 2016-01-05 2019-06-20 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Combination of histone deacetylase inhibitor and immunotherapy
WO2017136342A1 (en) 2016-02-02 2017-08-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells
AU2017336269B2 (en) * 2016-09-28 2022-06-16 Bavarian Nordic A/S Compositions and methods for enhancing the stability of transgenes in poxviruses
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
KR20190123328A (ko) 2017-03-09 2019-10-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 암 백신
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
CN110914310A (zh) 2017-03-10 2020-03-24 哈佛大学的校长及成员们 胞嘧啶至鸟嘌呤碱基编辑器
EP3658573A1 (en) 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020191241A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1164225B (it) 1983-05-13 1987-04-08 Anic Spa Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4844893A (en) 1986-10-07 1989-07-04 Scripps Clinic And Research Foundation EX vivo effector cell activation for target cell killing
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5108910A (en) 1989-08-22 1992-04-28 Immunex Corporation DNA sequences encoding fusion proteins comprising GM-CSF and IL-3
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
EP0676470A1 (en) 1989-10-16 1995-10-11 Amgen Inc. Stem cell factor
FR2668064B1 (fr) 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
KR100252547B1 (ko) 1991-09-05 2000-09-01 프레드 마리얀스키 폴리-또는 올리고누클레오티드의 세포로의 표적화된 전달
ES2180539T3 (es) 1991-10-23 2003-02-16 Nexell Therapeutics Inc Metodos para expandir selectivamente celulas madre.
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
ES2249760T3 (es) 1993-01-26 2006-04-01 The Trustees Of The University Of Pennsylvania (A Corporation Of Pennsylvania) Composiciones y procedimientos de administracion de materias geneticas.
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
CZ307995A3 (en) 1993-05-24 1996-10-16 Immunex Corp Ligands for flt3 receptors
US5405772A (en) 1993-06-18 1995-04-11 Amgen Inc. Medium for long-term proliferation and development of cells
US5744144A (en) 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
JPH10501681A (ja) 1994-02-22 1998-02-17 ダナ−ファーバー キャンサー インスティチュート 核酸送達システムならびにその合成および使用方法
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
ATE197765T1 (de) 1994-10-03 2000-12-15 Us Gov Health & Human Serv Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus
US6001349A (en) 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
US6514942B1 (en) 1995-03-14 2003-02-04 The Board Of Regents, The University Of Texas System Methods and compositions for stimulating T-lymphocytes
US5661064A (en) * 1995-11-13 1997-08-26 Micron Technology, Inc. Method of forming a capacitor having container members
KR20000022445A (ko) 1996-07-10 2000-04-25 크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 수상돌기 세포의 활성화 방법
AU4645697A (en) 1996-09-11 1998-04-02 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Aav4 vector and uses thereof
US6328969B1 (en) 1996-12-10 2001-12-11 Sloan-Kettering Institute For Cancer Research Method and compositions for stimulation of an immune response to a differentiation antigen stimulated by an altered differentiation antigen
CA2282300C (en) 1997-02-24 2011-08-02 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen
DE69839443D1 (de) 1997-05-08 2008-06-19 Biomira Inc Verfahren zur gewinnung von aktivierten t-zellen und mit antigen inkubierten antigenpräsentierenden zellen
US6576896B2 (en) 1997-12-12 2003-06-10 University Of Washington Electroosmotic fluidic device and related methods
US6123923A (en) * 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
DE69939169D1 (de) 1998-05-28 2008-09-04 Us Gov Health & Human Serv Aav5 vektoren und deren verwendung
US6114129A (en) 1998-06-26 2000-09-05 Biomira, Inc. Methods of detecting T-cell activation and treating disorders associated with T-cell dysfunction
US20030180314A1 (en) * 1998-07-10 2003-09-25 Degroot Anne Immunogenic, cross-clade, HIV peptides
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
US6407063B1 (en) 1998-10-02 2002-06-18 Ludwig Institute For Cancer Research Tumor antigens and CTL clones isolated by a novel procedure
WO2001018035A2 (en) * 1999-09-08 2001-03-15 Transgene S.A. Muc-1 derived peptides
EP1225907A4 (en) * 1999-10-05 2005-06-22 Epimmune Inc INDUCING CELLULAR IMMUNE RESPONSES TO HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
EP1232392B2 (de) 1999-10-12 2014-04-02 Oxoid (Ely) Limited Verbessertes verfahren zum nachweis von säure-resistenten bakterien der gattung helicobacter im stuhl
US6548062B2 (en) * 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
CA2404041A1 (en) 2000-03-28 2001-10-04 The Regents Of The University Of California Methods for increasing a cytotoxic t lymphocyte response in vivo
AUPQ776100A0 (en) 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
WO2002022685A2 (en) * 2000-09-11 2002-03-21 Kufe Donald W Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom
WO2002060953A2 (en) * 2000-12-15 2002-08-08 Agensys, Inc. Nucleic acid and encoded zinc transporter protein entitled 108p5h8 useful in treatment and detection of cancer
US20050048073A1 (en) * 2001-02-28 2005-03-03 De Groot Anne S. Methods of determining west nile virus epitopes and method of using the same
US6716627B2 (en) * 2001-12-20 2004-04-06 Isis Pharmaceuticals, Inc. Antisense modulation of mucin 1, transmembrane expression
EP1497649A4 (en) * 2002-04-22 2006-03-22 Dyax Corp FOR MUCIN POLYPEPTIDE SPECIFIC ANTIBODIES
GB0212036D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
EP1366850A1 (de) * 2002-05-27 2003-12-03 Schneeberger Holding AG Linearbewegungsführung mit einer führungsschiene und einer Zahnstange
WO2005046622A2 (en) 2003-11-12 2005-05-26 Therion Biologics Corporation Custom vectors for treating and preventing pancreatic cancer
ES2476990T3 (es) 2003-11-12 2014-07-15 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sistema para tratar y prevenir cáncer de mama

Similar Documents

Publication Publication Date Title
JP2004537252A5 (cg-RX-API-DMAC10.html)
JP2008503217A5 (cg-RX-API-DMAC10.html)
BR0213565A (pt) Anticorpo de anti-tnf alfa modificado
WO2007130455A3 (en) Compositions and methods for treatment of non-hodgkins lymphoma
JP2011520436A5 (cg-RX-API-DMAC10.html)
McCabe et al. Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses
JP2012509659A5 (cg-RX-API-DMAC10.html)
JP2017529059A5 (cg-RX-API-DMAC10.html)
ATE329030T1 (de) Nukleinsäure, welche einen von lektin abstammenden faktor zur präservierung von progenitorzellen kodiert
TW201129379A (en) Anti-Orai1 antigen binding proteins and uses thereof
JP2018506287A5 (cg-RX-API-DMAC10.html)
WO2003080856A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2019228032A1 (zh) 磷酸化多肽抗原疫苗及其制备方法和应用
NZ333203A (en) Tumour antigen proteins, genes thereof, and tumour antigen peptides
JP2021536239A5 (cg-RX-API-DMAC10.html)
WO2003029423A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
CN105985447B (zh) 一种白蛋白结合型肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途
JP6170076B2 (ja) HER2/neuポリペプチドを発現する癌細胞を認識する能力を有するCD8+T細胞を作製するための方法および材料
WO2005061531A1 (en) A superantigen fusion protein used for antitumor therapy and the preparation thereof
WO2003085124A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003031571A3 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
Richter et al. T‐cell epitope‐dependent immune response in inbred (C57BL/6J, SJL/J, and C3H/HeN) and transgenic P301S and Tg2576 mice
CN117797253A (zh) 一种能扩展t细胞抗原表位的肿瘤疫苗及其制备方法
CN116359509A (zh) 一种用于胃癌治疗的肿瘤新抗原筛选方法和新型纳米疫苗的制备方法及应用
WO2023030408A1 (zh) TGFβRII突变体及其应用